Arexvy Kit
Product Images NDC 58160-848

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Arexvy (NDC 58160-848). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glaxosmithkline Biologicals Sa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Arexvy Spl Graphic 01)

An instructional diagram showing a syringe drawing liquid from a vial labeled as the Adjuvant Suspension Component, indicating preparation of the respiratory syncytial virus vaccine recombinant, adjuvanted kit.*

FDA Label Image

Figure 2 (Arexvy Spl Graphic 02)

An instructional diagram showing a syringe positioned above a vial labeled '2,' which contains a lyophilized antigen component (powder). A downward arrow indicates that the syringe is to be inserted into the vial for reconstitution or preparation.*

FDA Label Image

Figure 3 (Arexvy Spl Graphic 03)

An instructional diagram showing a hand holding a syringe that is being twisted or unlocked from a vial. The image illustrates a step in preparing a vaccine dose, specifically for Arexvy, a respiratory syncytial virus vaccine recombinant, adjuvanted kit by GlaxoSmithKline Biologicals SA.*

FDA Label Image

Figure 4 (Arexvy Spl Graphic 04)

An instructional diagram showing a syringe being filled with reconstituted vaccine from a vial labeled with a number 2. A downward arrow indicates the direction of fluid transfer from vial to syringe. This likely illustrates preparation steps for the Arexvy respiratory syncytial virus vaccine recombinant, adjuvanted kit.*

FDA Label Image

Arexvy 10 Dose Carton (Arexvy Spl Graphic 05)

The image shows a packaging label for Arexvy, a Respiratory Syncytial Virus Vaccine, Adjuvanted in a kit form by GlaxoSmithKline Biologicals SA. The label includes instructions to combine one vial of lyophilized antigen component with one vial of adjuvant suspension component before use. It specifies the vaccine is for individuals 60 years of age and older and contains 10 doses each of the adjuvant suspension component and lyophilized antigen component.*

FDA Label Image

Arexvy Antigen Vial Label (Arexvy Spl Graphic 06)

Label from a vial of Arexvy Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted. This is the lyophilized antigen component vial, part of a two-vial kit. Label states it must be reconstituted with the adjuvant suspension and not used alone. Manufacturer is GlaxoSmithKline Biologicals.*

FDA Label Image

Arexvy Adjuvant Vial Label (Arexvy Spl Graphic 07)

Label for Arexvy Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted Adjuvant Suspension Component. The label states it is NOT TO BE USED ALONE and instructs to add to 1 vial of Lyophilized Antigen Component to form Arexvy. Manufactured by GlaxoSmithKline Biologicals SA. Includes NDC 58160-744-03 and barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.